Skip to main content
OpenTrials
Completed

NCT Number: NCT04765033

Trial on The Efficacy of Hypertonic Saline on Non-CF CSLD.

To determine the efficacy of nebulized 5% hypertonic saline on cough severity and quality of life, in children with non-CF CSLD.

Secondary Aims:

To determine the:

1. Efficacy of nebulized 5% hypertonic saline on airway microbiome, pulmonary exacerbation rate, healthcare utilization, and rescue antibiotics. 2. Efficacy of nebulized 5% hypertonic saline on lung function 3. Adverse effects of nebulized 5% hypertonic saline in children

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bronchiectasis Bronchial Diseases Chronic Cough Cough Pathological Conditions, Signs and Symptoms Respiration Disorders Respiratory Tract Diseases Signs and Symptoms Signs and Symptoms, Respiratory

Age range

3 month–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University Malaya Medical Centre

Kuala Lumpur, Lembah Pantai, 59100, Malaysia

About this study

Primary Aim:

To determine the efficacy of nebulized 5% hypertonic saline on cough severity and quality of life, in children with non-CF CSLD.

Here the investigators will be using validated pediatric cough questionnaires to asses this. Patients will answer these questionnaires at first recruitment ( -1 mth), at randomization (0 month) and after 3 mths of use of the nebulized study drug (+ 3 mths)

Secondary Aims:

To determine the:

  • Efficacy of nebulized 5% hypertonic saline on the airway microbiome, pulmonary exacerbation rate, healthcare utilization, and rescue antibiotics.

Here the investigators will be taking history on the exacerbations, use of antibiotics and healthcare utilization before and after use of the hypertonic saline. Furthermore, Nasopharyngeal swabs will be done to review possible changes in microbiota, again before and after use of the 5% HS.

  • Efficacy of nebulized 5% hypertonic saline on lung function. Here is investigators will be doing portable spirometry ( pre and post bronchodilator).

Patients will perform at randomization (0 month) and after 3 mths of use of the nebulized study drug (+ 3 mths)

  • Adverse effects of nebulized 5% hypertonic saline in children HS has been associated with side-effects. The investigators will monitor this. We will asses presence of these symptoms at randomization (0 month) and after 3 mths of use of the nebulized study drug (+ 3 mths) to ensure these are from the nebulizer.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients < 18 years old
  • Followed up in the paediatric respiratory clinic of UMMC with a diagnosis of CSLD

Exclusion criteria

  • Incomplete data or refusal to participate
  • Unwell and/or unable to stop HS and/or antibiotics of any preparation other than azithromycin ( EOD
  • On supplementary oxygen/home ventilation
  • Poorly controlled asthma (as in the GINA guidelines) or bronchoconstriction that precedes the use of hypertonic saline.
  • Oral antibiotics for less than 4 weeks before randomization for medication.
  • Fall in PEFR > 20% post 5% HS challenge test or a positive HS challenge test in young children, as mentioned below.

Treatment and study plan

Nebulized 5% Hypertonic saline

Drug

nebulized 0.9% saline

Other names: Placebo

Primary outcomes

  1. Change in the Short Parent-proxy cough quality of life (PC-QOL) score

    Time frame: at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug

    Short PCQOL: This is a validated cough quality-of-life(QoL) questionnaire for parents of children with chronic cough, with a translated Malay version. Minimal Important Difference(MID) of 0.9 has been found in the validation study.

    The answers are on a Likert scale from 1 (every time) to 7( none). A lower score denotes a lower quality of life.

    The patients will answer either the English or the translated Malay version

  2. Change in the Chronic Cough-specific QoL(CC-QOL) score

    Time frame: at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug

    Chronic cough-specific QOL: This is a validated cough QoL questionnaire to be answered by children 7 years till 18 years old with a MID of about 1.1. The answers are in a Likert scale from 1 ( every time) to 7( none). A lower score denotes a lower quality of life.

    The patients will answer either the English or the translated Malay version

Secondary outcomes

  1. Airway microbiome

    Time frame: At day 1 of randomization, at 3 months of use of study drug

    DNA will be extracted from swabs using the Qiagen DNA Isolation Kit in accordance with the manufacturer's instructions. Bacterial profiling utilised the 16S rRNA gene targeting variable regions V3 - V4 will be carried out using Nextseq 2500 platform. Resulting raw fastq data will be processed using Dada2 R package and exported into phyloseq Rprogram for downstream analysis. The Alpha diversity will be measured using the Shannon and Simpson diversity indices while the beta diversity will be accessed using principle coordinate analysis and Permutational multivariate analysis of variance(PERMANOVA). Differentially abundant taxa will be identified by comparing the fold-change different using DESeq2.

  2. Number of Exacerbations

    Time frame: at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug

    Defined as having one major and 2 minor OR 2 major criteria irrespective of whether antibiotics are prescribed.

    Criteria for exacerbation:

    Major: (1) Wet cough over 72 hours, (2) Severe cough over 72 hours Minor: (1) Change in Sputum colour, (2) Chest pain, (3) SOB, (4) Haemoptysis, (5) + ve Chest signs

    At -1 month, we will look at the no of exacerbations in the past 1 year. Before the use of the study drug and after 3 months of use of the study drug, we will look at the no of exacerbations in the preceding 1 month and 3 months, respectively.

  3. Number of Unscheduled Health Care Visits

    Time frame: at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug

    any unscheduled doctor visits for cough, shortness of breath or any other respiratory associated symptom.

    This will be for the last 3 months before day 1 of randomization and after 3 months of use of study drug

  4. No of episodes of rescue antibiotics

    Time frame: at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug

    Prescription of antibiotics (including nebulized antibiotics) at least for 3 days for respiratory associated symptoms.

    This will be in the past 3 months, before randomization and during the next 3 months, while on the study drug.

  5. FEV1

    Time frame: At day 1 of randomization, at 3 months of use of study drug

    FEV1 will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FEV1 value will be converted into z-score by using GrowingLungs software.

  6. FVC

    Time frame: At day 1 of randomization, at 3 months of use of study drug

    FVC will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FVC value will be converted into z-score by using GrowingLungs software.

  7. FEF 25-75%

    Time frame: At day 1 of randomization, at 3 months of use of study drug

    FEF 25-75% will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FEF25-75% value will be converted into z-score by using GrowingLungs software.

  8. PEFR ( pre and post), if possible

    Time frame: at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug

    The best PEFR measure out of 3 reproducible attempts ( both pre and post 4 puffs of MDI Salbutamol), performed when relatively well and stable, will be recorded for analysis.

  9. Cough diary

    Time frame: at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug

    The cough score will be assessed using the Malay version, used in the HOspitalised Pneumonia Extended study, whereby the cough score will be tabulated daily.

    The cough diary has recordings for both day time cough: score 0 ( no cough) till score 5 ( Cannot perform most usual day-time activity due to severe coughing).

    The night cough is scored score 0 ( no cough) till score 5 ( distressing cough.).

    A higher score indicates more severe cough.

  10. Number of Adverse events

    Time frame: At day 1 of randomization, at 3 months of use of study drug

    cough, haemoptysis, sore throat, throat burning, chest tightness, hoarseness of voice.

Sponsors and collaborators

Lead sponsor

University of Malaya

Other

Registry information

Official study title

Efficacy of Nebulised 5% Hypertonic Saline in Children With Chronic Suppurative Lung Disease

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Feb 21, 2021
Registry last updated
Dec 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.